Returns diminishing, but kidney function kept improving a bit. The only hard data given concerns eGFR, though they say none of the patients died, and they were hospitalized less than patients in similar trials. Without the ability to compare population characteristics among trials, that doesn't mean much, of course.
News released after hours today, and I'm seeing no movement in the stock (not checking to to see if it's halted).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.